CCG-232601

Cat. No.:	HY-111432
CAS No.:	1922099-21-5
Molecular Formula:	$C_{24}H_{20}ClF_2N_3O_2$
Molecular Weight:	455.88
Target:	Ras
Pathway:	GPCR/G Protein
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.



BIOLOGICAL ACTIVITY

Description	CCG-232601 (compound 8f) is a potent and orally active Rho/MRTF/SRF transcriptional pathway inhibitor. CCG-232601 inhibits the development of Bleomycin-induced dermal fibrosis in mice. CCG-232601 has the potential for the research of antifibrotic for systemic scleroderma[1].
In Vitro	CCG-232601 inhibits SRE.L activity with an IC_{50} of 0.55 μM[1]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.
In Vivo	CCG-232601 (50 mg/kg; i.g.; intracutaneous injections of bleomycin; daily for 14 days) inhibits bleomycin-induced skin fibrosis in mice[1]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.

REFERENCES

[1]. Hutchings KM, et al. Pharmacokinetic optimitzation of CCG-203971: Novel inhibitors of the Rho/MRTF/SRF transcriptional pathway as potential antifibrotic therapeutics for systemic scleroderma. Bioorg Med Chem Lett. 2017 Apr 15;27(8):1744-1749.

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com
Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA